News

An In-Depth Look at Paysign's 2024 Patient Affordability Success

An In-Depth Look at Paysign's 2024 Patient Affordability Success

Paysign's Impressive 2024 Performance in Patient Affordability

Paysign, Inc. (NASDAQ: PAYS), a front-runner in providing patient affordability solutions, unveiled its annual performance analysis for the year. This analysis sheds light on the significant impact of their innovative financial technology products and services aimed at improving patient access to necessary medications. In the fiscal year, Paysign's advancements enabled pharmaceutical copay programs to flourish, reinforcing the company's position as a leader in the healthcare payment processing sector.

Transforming Patient Affordability Solutions

In 2024, Paysign introduced a groundbreaking feature known as dynamic business rules, which has effectively shielded clients from the adverse effects of copay maximizers. This innovative approach saved clients over $100 million throughout the year, highlighting the company's commitment to enhancing the economic experience for both patients and pharmaceutical sponsors. With an impressive 97% accuracy rate in identifying affected claims on the first fill, this technology represents a significant leap in the industry.

Achievements and Milestones

Paysign's annual performance data reveals a number of remarkable accomplishments within the patient affordability landscape in 2024:

  • Saved over $100 million for pharmaceutical programs by preventing fund diversion.
  • Supported more than 66 retail and specialty pharmaceutical programs across varying therapeutic classes.
  • Assisted over 500,000 unique patients during the year, marking a significant increase from the previous year.
  • Contributed to programs that provided over $600 million towards prescription fulfillment in various therapeutic areas.

Leadership Insights on the 2024 Results

Matt Turner, the President of Patient Affordability at Paysign, expressed his enthusiasm regarding the company's achievements. He noted that, "2024 was a pivotal year for our patient affordability business. An increasing number of the world’s largest pharmaceutical companies trusted our technologies to help remove financial hurdles their patients face when starting or continuing therapy. Our dedication has helped ease the financial strain many patients encounter."

Continuing to Broaden Presence in Healthcare

Paysign's results underscore its consistent growth trajectory and prominent standing in the healthcare industry. The substantial savings achieved for both patients and clients illustrate Paysign's efficacy and commitment to developing effective solutions tailored to the unique challenges faced by stakeholders in the healthcare ecosystem.

Future Innovations and Commitment

Mark Newcomer, the Chief Executive Officer of Paysign, emphasized the importance of innovation in their offerings. He remarked, "Achieving these milestones reflects our commitment to enhancing our patient affordability suite of solutions. Our ongoing expansion into healthcare and life sciences is exciting, and we remain dedicated to improving our capabilities in this vital sector."

At the core of Paysign’s patient affordability platform lies a customizable suite of tools designed to address the distinct needs of each copay assistance program and pharmaceutical manufacturer’s branding strategy. The capacity for real-time adjustments through dynamic business rules ensures that patients and providers experience seamless benefit interactions.

About Paysign

Paysign, Inc. excels in delivering prepaid card programs, patient affordability solutions, and integrated payment processing services tailored for various industries, including healthcare, pharmaceutical, retail, and hospitality. Founded in 1995 and based in southern Nevada, Paysign crafts innovative payment solutions focused on enhancing customer experience, lowering operational costs, and fostering loyalty among partners.

Frequently Asked Questions

What is Paysign, Inc. known for?

Paysign, Inc. is recognized for its comprehensive patient affordability solutions and integrated payment processing services tailored for various industries.

How much did Paysign save for pharmaceutical sponsors in 2024?

Paysign saved over $100 million for pharmaceutical program sponsors in 2024 by implementing innovative financial technology solutions.

What new technology did Paysign introduce in 2024?

Paysign introduced dynamic business rules, allowing for real-time modifications to reduce the impact of copay maximizers on patients and sponsors.

How many patients did Paysign assist in 2024?

Paysign assisted over 500,000 unique patients in 2024, more than doubling the figure from the previous year.

What industries use Paysign's services?

Paysign's services cater primarily to healthcare, pharmaceutical, retail, and hospitality sectors, providing customized payment solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Core Natural Resources Strikes Gold in Q3, Surpassing Targets

Updated Category News Views 145

Core's Strong Q3: A Closer Look The latest buzz in the coal sector is all about Core Natural Resources, Inc. (NYSE: CNR) delivering a sturdy third quarter performance. These folks are playing the market like a fiddle, dishing out $9 million in net income and clocking $165.2 million in adjusted EBITDA. For a sector rife with dust and sweat, that's not too shabby. A Closer...

Continue Reading
S&P 500 Drop: A Market Glitch or Future Trend?

Updated Category News Views 17

A Sudden Jolt in a Trending Market Mornings like these make you question your coffee strength. A major market dip, with the S&P 500 shedding 3.51%, is like a slap to the face, especially when the Nasdaq Composite takes a 5.24% nosedive. The Dow isn't spared, dropping 2.45%. But, let's not lose our heads here. Today is a blip, a pixel in the bigger picture where the S&P...

Continue Reading
Pavlus Travel's Bucket-List Trips in High Demand for 2027

Updated Category News Views 46

Luxury Travel is Having a Moment A fancy vacation isn't just a postcard on the wall anymore—it's now, more than ever, a box folks are itching to check off their lists. Call it a midlife shift or just the world shrugging off its pandemic blues, but high-end travelers are saying, "The time is now," and they're serious. Pavlus Travel, a top name in the lux travel space,...

Continue Reading
Energy Fuels' Bold Moves: An Investor's Analysis

Updated Category News Views 149

Energy Fuels Sets the Stage An era of rare earths and uranium dominance—this is the gauntlet Energy Fuels seems to be throwing down. With the acquisition of ASM and a Korean Metals Plant under its belt, they're flexing a strategy designed to boost the west's autonomous rare earth supply chain. That ain't a small feat, and it looks like they're gearing up for a battle...

Continue Reading
Endava Faces Class Action for Securities Violation

Updated Category News Views 68

Endava's Legal Storm Clouds Gather Well, well, looks like Endava plc (NYSE: DAVA) has found itself knee-deep in a legal quagmire, thanks to some not-so-transparent financial antics. Investors are up in arms, and the fine folks at DJS Law Group are stepping in, filing a class action lawsuit against Endava for overstating their financial health. They allege that Endava made...

Continue Reading
Fedora and Clarion Boost Oncology Practice Performance

Updated Category News Views 77

Hell of a Pair-Up: Fedora and Clarion Focus on Oncology Well, here's a setup that doesn't scream about blue chip stocks—but it's swimming in opportunity all the same. Fedora Healthcare Solutions just shook hands with Clarion, cementing a deal that's piqued my interest for its potential to green-light some real progress for independent oncology practices. These are not...

Continue Reading
Perpetua's Bold Moves Elevate Idaho's Stibnite Gold Project

Updated Category News Views 91

Perpetua Resources Sparking New Conversations Alright, fasten your seatbelts, folks—Perpetua Resources is causing a buzz with its Stibnite Gold Project. If you blink, you might miss what's happening down in Idaho. They've started throwing some serious weight around with fresh gold discoveries that not only promise ounces but maybe some juicy returns for those keeping a...

Continue Reading
Minesto's Tidal Project Nets EU Recognition & Funding

Updated Category News Views 64

Tapping Into the Tides: Minesto's Strategic Leap Table flipping news coming in from Gothenburg! Minesto—the ocean energy trailblazer—is making waves again, snagging the EU's STEP Seal for its Euro Dragon Farm project in Ireland. You couldn't ask for a better boon from Brussels—they're sinking a cool EUR 20.2 million in grant funds into this tidal energy venture....

Continue Reading
Admetec Shines Bright with New High-Magnification Headlights

Updated Category News Views 56

Admetec's Leap into Advanced Optical Solutions In the world of optical magnification, getting the right balance of visibility and comfort hasn't always been a straightforward journey. Now, Admetec, coming out of Haifa, Israel, is throwing a game-changer into the mix with their announcement of the Butterfly EVO+ and Orchid+ series. These ain't just any old headlights;...

Continue Reading
Implantica's RefluxStop® Makes U.S. Debut with a Bang

Updated Category News Views 94

A Fresh Chapter in U.S. Medtech There’s a new kid on the block, folks, and it's making waves in the medtech scene. Implantica has just announced the successful completion of their first RefluxStop® procedures in the good ol' U.S. of A. That's right, we've got another player in the game aiming to shake things up, and frankly, it's about time someone brought a fresh...

Continue Reading

Top 5 Most Recently Viewed Articles

Alys Pharmaceuticals' Groundbreaking Submission for ALY-301 Trial

Updated Category News Views 218

Alys Pharmaceuticals' CTA Submission for ALY-301 Study Alys Pharmaceuticals, Inc. has made an exciting announcement regarding its Clinical Trial Application (CTA) for ALY-301, a pioneering mast cell selective c-Kit inhibitor designed to treat Cold Urticaria. This represents a major advancement in immune-dermatology, showcasing Alys' commitment to developing targeted...

Continue Reading
Ensurge Micropower ASA's Upcoming Financial Opportunities

Updated Category News Views 50

Exploring Ensurge Micropower ASA’s Financial Strategies Ensurge Micropower ASA, a significant player in advanced battery technology, has recently made headlines with its strategic financial plans designed to enhance its capital resources. The company has unveiled a private share placement aiming to secure NOK 75 million, signaling a proactive stance toward financing its...

Continue Reading
Revamped iScanner App Unveils Cutting-Edge Document Repair Feature

Updated Category News Views 201

Introducing the New iScanner Edge Repair Feature Small business owners and remote workers often face challenges when it comes to scanning documents that are stapled or have uneven edges. Thankfully, the iScanner app offers a remarkable AI solution designed to ensure that every scan is perfect, regardless of the original document's condition. What is Edge Repair? The...

Continue Reading
Sprott Physical Uranium Trust Secures $200 Million in Funding

Updated Category News Views 262

Sprott Physical Uranium Trust Completes Major Financing Sprott Inc. recently announced the successful closure of an upsized bought deal public offering for the Sprott Physical Uranium Trust. This significant financial step involved issuing 11,600,000 units at a price of $17.25 per unit, resulting in total gross proceeds of approximately $200 million. Canaccord Genuity...

Continue Reading
The MATTIE Fund's Transformative Grants Empower Women's Health

Updated Category News Views 408

The MATTIE Fund's New Grants Highlight Commitment to Women The MATTIE Fund proudly unveils its first round of grants, totaling $1.5 million, aimed at empowering organizations dedicated to supporting women's mental health, emotional resilience, and overall well-being. This initiative is a significant step toward addressing the needs of diverse and marginalized women and...

Continue Reading